Pipeline
The company has three programs in place. The lead program, CVac™ has completed Phase IIa clinical trials and focuses on the development of an ex-vivo immunotherapy for ovarian cancer. Prima is now undertaking a Phase IIb clinical study in the US and Australia, and aims to commence global Phase III programs in 2011, with a goal of commercialization of CVac™ in multiple world markets.
The second program is focusing on the identification and development of a monoclonal antibody to cripto-1. Monoclonal antibodies have been a major success in recent improvements of cancer treatment. Cripto-1 is a component of the endothelial growth factor complex, and neutralizing this important protein will enable Prima to target multiple tumour types.
The third is a collaborative venture with the University of New South Wales and University of Queensland to create a technology enabling oral administration of vaccines that are currently injected. The lead target for this program is to create an oral vaccine against Human Papilloma Virus (HPV), a virus associated with development of cervical cancer.
|
|